Recent News

• 06.11.2025 - Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
• 06.11.2025 - Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
• 06.11.2025 - Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.04.2025 - Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
• 06.04.2025 - Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
• 06.04.2025 - Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
• 05.28.2025 - Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
• 05.28.2025 - Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Recent Filings

• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - EX-99.1 EX-99.1
• 06.04.2025 - 8-K Current report
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.09.2025 - 4 Statement of changes in beneficial ownership of securities